Test Bank for LEHNE’S
PHARMACOTHERAPEUTICS FOR ADVANCED
PRACTICE NURSES AND PHYSICIAN
ASSISTANTS 3RD EDITION Practice Exam 2026
| Most Tested Questions Collection &
Verified Detailed Answers | Tutor Verified
Success Exam) Graded A+
Section 1: Basic Principles of Pharmacology
1. A patient asks the nurse practitioner how a medication that is
administered as a pill knows where to go in the body to work. What
is the best response?
a) "Medications have a specific 'homing' signal that directs them to
their target organ."
b) "The medication is distributed throughout the body and interacts
with receptors where it has an affinity."
c) "The digestive system breaks down the pill and sends the active
ingredient to the correct location."
d) "The medication is attracted to areas of inflammation or disease."
Answer: b
Rationale: The distribution of a drug is systemic; it goes everywhere.
Its therapeutic effect is determined by its selective binding to
receptors for which it has a high affinity, not by a specific targeting
mechanism. Option A is incorrect. Option C is only a part of the
process (absorption) and doesn't explain how the drug "knows"
where to go. Option D is true for some drugs but not a general
principle.
,2. A drug with a high first-pass effect would most likely be
administered by which route?
a) Oral
b) Sublingual
c) Intravenous
d) Subcutaneous
Answer: a
Rationale: The first-pass effect refers to the extensive metabolism of
a drug in the liver before it reaches systemic circulation. This is most
pronounced when a drug is absorbed from the gastrointestinal tract
and travels via the portal vein to the liver. Sublingual (B), IV (C), and
subcutaneous (D) routes bypass the liver's first-pass metabolism to
varying degrees.
3. A patient is receiving a drug that is a strong agonist at the mu-
opioid receptor. What effect is expected?
a) Blockade of pain signals
b) Activation of pain relief pathways
c) No effect, as a strong agonist has no clinical effect
d) Reversal of opioid-induced respiratory depression
Answer: b
Rationale: An agonist is a drug that binds to a receptor and activates
it, producing a response. A strong agonist at the mu-opioid receptor
will effectively activate the receptor, leading to analgesia.
Antagonists (A and D) block receptors. Option C is incorrect; a strong
agonist produces a maximal effect.
4. A patient's medication has a half-life of 4 hours. How long will it
take for the drug to reach a steady-state concentration?
a) 4 hours
b) 8 hours
c) 20 hours
d) 40 hours
,Answer: c
Rationale: Steady-state is reached in approximately 4-5 half-lives.
Therefore, 4 half-lives x 4 hours = 16 hours, or 5 half-lives x 4 hours =
20 hours. Option C (20 hours) is the best estimate.
5. Which of the following is the most accurate description of a
drug's therapeutic index?
a) The ratio of the dose required to produce a therapeutic effect to
the dose that produces a toxic effect.
b) The ratio of the dose that is toxic to 50% of the population
(TD50) to the dose that is effective in 50% of the population (ED50).
c) The range of doses between the minimum effective concentration
and the minimum toxic concentration.
d) The measure of how quickly a drug reaches its peak concentration.
Answer: b
Rationale: The therapeutic index is a measure of a drug's safety,
calculated as the ratio of TD50 to ED50. A high TI indicates a wide
margin of safety. Option A is a general description, but B is the formal
pharmacologic definition. Option C describes the therapeutic window.
Option D describes the rate of absorption.
6. A patient with a history of liver cirrhosis is prescribed a
medication that is highly protein-bound. What is a primary
concern?
a) The drug's absorption will be decreased.
b) The drug's free concentration will be increased, leading to a
higher risk of toxicity.
c) The drug's half-life will be significantly shortened.
d) The drug will be more rapidly metabolized.
Answer: b
Rationale: Liver disease can lead to decreased production of serum
albumin. With fewer binding sites, a higher fraction of the drug will
exist in the free, active form. This can lead to increased
, pharmacologic effect and toxicity. Absorption is not directly affected
by protein binding. Metabolism (C) is likely impaired, not shortened.
7. The nurse practitioner prescribes a drug with a small volume of
distribution. This suggests the drug:
a) Is widely distributed into tissues.
b) Is highly lipid-soluble.
c) Is primarily confined to the plasma or extracellular fluid.
d) Will have a very long half-life.
Answer: c
Rationale: The volume of distribution (Vd) relates the amount of drug
in the body to the concentration of drug in the plasma. A small Vd
indicates that the drug is primarily in the blood or well-perfused
organs. A large Vd indicates widespread distribution into tissues.
Highly lipid-soluble drugs (B) typically have a large Vd. A large Vd is
more associated with a long half-life (D).
8. Which of the following drug interactions would be classified as
pharmacodynamic?
a) Drug A inhibits the metabolism of Drug B, leading to increased
levels of Drug B.
b) Drug A and Drug B both cause QT prolongation, increasing the
risk of arrhythmias.
c) Drug A binds to plasma proteins, displacing Drug B and increasing
its free concentration.
d) Drug A decreases the gastrointestinal motility, reducing the
absorption of Drug B.
Answer: b
Rationale: A pharmacodynamic interaction occurs when two drugs
have additive, synergistic, or antagonistic effects at the same or
different receptor sites. Both causing QT prolongation is an example
of an additive pharmacodynamic effect. Options A, C, and D are
PHARMACOTHERAPEUTICS FOR ADVANCED
PRACTICE NURSES AND PHYSICIAN
ASSISTANTS 3RD EDITION Practice Exam 2026
| Most Tested Questions Collection &
Verified Detailed Answers | Tutor Verified
Success Exam) Graded A+
Section 1: Basic Principles of Pharmacology
1. A patient asks the nurse practitioner how a medication that is
administered as a pill knows where to go in the body to work. What
is the best response?
a) "Medications have a specific 'homing' signal that directs them to
their target organ."
b) "The medication is distributed throughout the body and interacts
with receptors where it has an affinity."
c) "The digestive system breaks down the pill and sends the active
ingredient to the correct location."
d) "The medication is attracted to areas of inflammation or disease."
Answer: b
Rationale: The distribution of a drug is systemic; it goes everywhere.
Its therapeutic effect is determined by its selective binding to
receptors for which it has a high affinity, not by a specific targeting
mechanism. Option A is incorrect. Option C is only a part of the
process (absorption) and doesn't explain how the drug "knows"
where to go. Option D is true for some drugs but not a general
principle.
,2. A drug with a high first-pass effect would most likely be
administered by which route?
a) Oral
b) Sublingual
c) Intravenous
d) Subcutaneous
Answer: a
Rationale: The first-pass effect refers to the extensive metabolism of
a drug in the liver before it reaches systemic circulation. This is most
pronounced when a drug is absorbed from the gastrointestinal tract
and travels via the portal vein to the liver. Sublingual (B), IV (C), and
subcutaneous (D) routes bypass the liver's first-pass metabolism to
varying degrees.
3. A patient is receiving a drug that is a strong agonist at the mu-
opioid receptor. What effect is expected?
a) Blockade of pain signals
b) Activation of pain relief pathways
c) No effect, as a strong agonist has no clinical effect
d) Reversal of opioid-induced respiratory depression
Answer: b
Rationale: An agonist is a drug that binds to a receptor and activates
it, producing a response. A strong agonist at the mu-opioid receptor
will effectively activate the receptor, leading to analgesia.
Antagonists (A and D) block receptors. Option C is incorrect; a strong
agonist produces a maximal effect.
4. A patient's medication has a half-life of 4 hours. How long will it
take for the drug to reach a steady-state concentration?
a) 4 hours
b) 8 hours
c) 20 hours
d) 40 hours
,Answer: c
Rationale: Steady-state is reached in approximately 4-5 half-lives.
Therefore, 4 half-lives x 4 hours = 16 hours, or 5 half-lives x 4 hours =
20 hours. Option C (20 hours) is the best estimate.
5. Which of the following is the most accurate description of a
drug's therapeutic index?
a) The ratio of the dose required to produce a therapeutic effect to
the dose that produces a toxic effect.
b) The ratio of the dose that is toxic to 50% of the population
(TD50) to the dose that is effective in 50% of the population (ED50).
c) The range of doses between the minimum effective concentration
and the minimum toxic concentration.
d) The measure of how quickly a drug reaches its peak concentration.
Answer: b
Rationale: The therapeutic index is a measure of a drug's safety,
calculated as the ratio of TD50 to ED50. A high TI indicates a wide
margin of safety. Option A is a general description, but B is the formal
pharmacologic definition. Option C describes the therapeutic window.
Option D describes the rate of absorption.
6. A patient with a history of liver cirrhosis is prescribed a
medication that is highly protein-bound. What is a primary
concern?
a) The drug's absorption will be decreased.
b) The drug's free concentration will be increased, leading to a
higher risk of toxicity.
c) The drug's half-life will be significantly shortened.
d) The drug will be more rapidly metabolized.
Answer: b
Rationale: Liver disease can lead to decreased production of serum
albumin. With fewer binding sites, a higher fraction of the drug will
exist in the free, active form. This can lead to increased
, pharmacologic effect and toxicity. Absorption is not directly affected
by protein binding. Metabolism (C) is likely impaired, not shortened.
7. The nurse practitioner prescribes a drug with a small volume of
distribution. This suggests the drug:
a) Is widely distributed into tissues.
b) Is highly lipid-soluble.
c) Is primarily confined to the plasma or extracellular fluid.
d) Will have a very long half-life.
Answer: c
Rationale: The volume of distribution (Vd) relates the amount of drug
in the body to the concentration of drug in the plasma. A small Vd
indicates that the drug is primarily in the blood or well-perfused
organs. A large Vd indicates widespread distribution into tissues.
Highly lipid-soluble drugs (B) typically have a large Vd. A large Vd is
more associated with a long half-life (D).
8. Which of the following drug interactions would be classified as
pharmacodynamic?
a) Drug A inhibits the metabolism of Drug B, leading to increased
levels of Drug B.
b) Drug A and Drug B both cause QT prolongation, increasing the
risk of arrhythmias.
c) Drug A binds to plasma proteins, displacing Drug B and increasing
its free concentration.
d) Drug A decreases the gastrointestinal motility, reducing the
absorption of Drug B.
Answer: b
Rationale: A pharmacodynamic interaction occurs when two drugs
have additive, synergistic, or antagonistic effects at the same or
different receptor sites. Both causing QT prolongation is an example
of an additive pharmacodynamic effect. Options A, C, and D are
